

Web Table 1. Sensitivity analysis of stricter definition of Types I and II endometrial carcinoma in the NIH-AARP Diet and Health Study, 1995-2006

		Subtypes ^a		P _{heterogeneity} ^c
		Type I (n=864) RR (95% CI) ^b	Type II (n=90) RR (95% CI) ^b	
Age at menarche (years)	≥15 vs. <13	0.77 (0.59,1.00)	0.60 (0.25,1.40)	0.41
Age at menopause (years)	≥55 vs. <45	2.26 (1.68,3.05)	1.04 (0.39,2.80)	0.16
Menopausal hormone therapy	Ever vs. never user	1.15 (0.99,1.33)	0.72 (0.45,1.17)	0.003
Duration of menopausal hormone therapy use	≥10 years vs. never user	2.07 (1.68,2.55)	1.11 (0.52,2.38)	0.01
Oral contraceptive use	Ever vs. never user	0.70 (0.60,0.82)	0.52 (0.31,0.88)	0.10
Duration of oral contraceptive use	≥10 years vs. never user	0.60 (0.46,0.79)	0.51 (0.20,1.30)	0.11
Parous	Parous vs. nulliparous	0.68 (0.58,0.80)	0.85 (0.51,1.41)	0.66
Age at first birth (years)	>30 vs. nulliparous	0.60 (0.44,0.82)	0.51 (0.17,1.50)	0.46
Parity (births)	≥ 3 vs. nulliparous	0.64 (0.54,0.77)	0.79 (0.45,1.38)	0.60
Race	Black vs. white	0.57 (0.39,0.84)	2.66 (1.39,5.11)	0.001
Education	≥ High school vs. <high school	1.07 (0.92,1.25)	0.85 (0.54,1.34)	0.16
Body mass index (kg/m ²)	≥ 30 vs. <30	2.88 (2.51,3.31)	1.77 (1.13,2.77)	0.001
Frequency of vigorous physical activity	3+ times/week vs. never/rarely ≥ 24 grams/day vs. 0 grams/day	0.82 (0.69,0.98)	0.58 (0.33,1.02)	0.09
Alcohol intake	grams/day	1.07 (0.76,1.49)	-	-
Smoking status	Ever vs. never smoker	0.88 (0.77,1.01)	0.65 (0.42,1.00)	0.16
Diabetes	Yes vs. no	1.09 (0.86,1.37)	1.80 (0.97,3.31)	0.08
1st degree family history of breast cancer	Yes vs. no	0.85 (0.68,1.06)	2.13 (1.29,3.51)	0.002
1st degree family history of other cancer	Yes vs. no	1.12 (0.98,1.29)	1.43 (0.93,2.19)	0.47

a Sensitivity analysis with restricted definition of Types I and II cases.

b Adjusted for age (continuous), OC use (ever/never), MHT use (ever/never), parity (nulliparous,1,2,3+), BMI (<30 vs 30+ kg/m²), menarche (<13, 13-14, 15+), age at menopause (premenopausal, <45, 45-49, 50-54, 55+ years), race (white/non-white) and smoking status (never, former, current smoker). Unknown/missing set as a separate category within each factor.

c P value from logistic regression of case-only analysis of histological types comparing each risk factor, adjusting for same covariates as above and person-years.

Web Table 2. Sensitivity analysis of reclassification of grade 3+ endometrioid as Type II endometrial carcinoma in the NIH-AARP Diet and Health Study, 1995-2006

		Subtypes ^a		P _{heterogeneity} ^c
		Type I	Type II (n=291)	
		RR (95% CI) ^b	RR (95% CI) ^b	
Age at menarche (years)	≥15 vs. <13	0.87 (0.70,1.08)	0.52 (0.31,0.87)	0.16
Age at menopause (years)	≥55 vs. <45	2.24 (1.73,2.91)	1.27 (0.77,2.09)	0.07
Menopausal hormone therapy	Ever vs. never user	1.20 (1.06,1.36)	0.92 (0.71,1.19)	0.010
Duration of menopausal hormone therapy use	≥10 years vs. never user	2.06 (1.72,2.47)	1.83 (1.29,2.61)	0.04
Oral contraceptive use	Ever vs. never user	0.71 (0.62,0.81)	0.78 (0.60,1.02)	0.51
Duration of oral contraceptive use	≥10 years vs. never user	0.60 (0.47,0.76)	0.61 (0.37,0.99)	0.45
Parous	Parous vs. nulliparous	0.68 (0.59,0.78)	0.75 (0.57,1.00)	0.50
Age at first birth (years)	>30 vs. nulliparous	0.60 (0.46,0.79)	0.60 (0.35,1.04)	0.94
Parity (births)	≥ 3 vs. nulliparous	0.61 (0.52,0.71)	0.76 (0.56,1.03)	0.27
Race	Black vs. white	0.53 (0.38,0.75)	1.89 (1.26,2.83)	<0.0001
Education	≥ High school vs. <high school	1.07 (0.94,1.22)	0.85 (0.66,1.09)	0.09
Body mass index (kg/m ²)	≥ 30 vs. <30	3.04 (2.70,3.43)	2.04 (1.60,2.62)	0.0004
Frequency of vigorous physical activity	3+ times/week vs. never/rarely	0.79 (0.68,0.92)	0.67 (0.49,0.91)	0.34
Alcohol intake	≥ 24 grams/day vs. 0 grams/day	1.03 (0.78,1.37)	0.56 (0.27,1.17)	0.38
Smoking status	Ever vs. never smoker	0.87 (0.78,0.98)	0.82 (0.65,1.03)	0.87
Diabetes	Yes vs. no	1.16 (0.95,1.41)	1.80 (1.28,2.55)	0.04
1st degree family history of breast cancer	Yes vs. no	0.81 (0.66,0.98)	1.29 (0.93,1.79)	0.02
1st degree family history of other cancer	Yes vs. no	1.01 (0.89,1.14)	1.12 (0.88,1.43)	0.55

a Sensitivity analysis with re classification of grade3+ endometrioid adenocarcinoma and adenocarcinoma NOS as Types II cases.

b Adjusted for age (continuous), OC use (ever/never), MHT use (ever/never), parity (nulliparous,1,2,3+), BMI (<30 vs 30+ kg/m²), menarche (<13, 13-14, 15+), age at menopause (premenopausal, <45, 45-49, 50-54, 55+ years), race (white/non-white) and smoking status (never, former, current smoker). Unknown/missing set as a separate category within each factor.

c P value from logistic regression of case-only analysis of histological types comparing each risk factor, adjusting for same covariates as above and person-years.

Web Table 3. Sensitivity analysis of endometrial carcinoma cases with stage data in the NIH-AARP Diet and Health Study, 1995-2006

		Stage					
		In Situ/Localized			Metastases/Distant		
		Type I ^a (n=617) RR (95% CI) ^b	Type II ^a (n=35) RR (95% CI) ^b	P _{heterogeneity} ^c	Type I ^a (n=124) RR (95% CI) ^b	Type II ^a (n=31) RR (95% CI) ^b	P _{heterogeneity} ^c
Age at menarche (years)	≥15 vs. <13	0.81 (0.60,1.01)	0.25 (0.03,1.90)	0.35	0.40 (0.16,0.99)	0.61 (0.14,2.66)	0.80
Age at menopause (years)	≥55 vs. <45	2.10 (1.46,3.03)	2.89 (0.58,14.46)	0.63	2.32 (1.12,4.79)	1.09 (0.22,5.46)	0.91
Menopausal hormone therapy	Ever vs. never user	1.20 (1.01,1.42)	0.73 (0.35,1.55)	0.16	1.13 (0.77,1.66)	0.39 (0.15,1.00)	0.01
Duration of menopausal hormone therapy use	≥10 years vs. never user	2.33 (1.84,2.96)	2.61 (1.08,6.33)	0.63	1.67 (0.92,3.02)	0.27 (0.04,2.11)	0.01
Oral contraceptive use	Ever vs. never user	0.71 (0.59,0.86)	1.11 (0.54,2.32)	0.33	0.61 (0.40,0.93)	0.83 (0.37,1.90)	0.38
Duration of oral contraceptive use	≥10 years vs. never user	0.62 (0.45,0.86)	0.62 (0.14,2.72)	0.81	0.35 (0.14,0.88)	0.76 (0.17,3.34)	0.22
Parous	Parous vs. nulliparous	0.68 (0.56,0.82)	0.97 (0.40,2.37)	0.27	0.61 (0.41,0.92)	0.88 (0.36,2.17)	0.64
Age at first birth (years)	>30 vs. nulliparous	0.57 (0.39,0.83)	0.37 (0.04,3.05)	0.66	0.64 (0.29,1.40)	-	-
Parity (births)	≥ 3 vs. nulliparous	0.60 (0.49,0.74)	0.74 (0.27, 1.97)	0.49	0.59 (0.37,0.95)	1.01 (0.39, 2.60)	0.54
Race	Black vs. white	0.60 (0.38,0.94)	2.39 (0.82,6.97)	0.02	1.65 (0.86,3.20)	1.84 (0.54,6.01)	0.34
Education	≥ High school vs. <high school	1.16 (0.97,1.39)	0.68 (0.33,1.41)	0.09	0.94 (0.63,1.40)	0.73 (0.35,1.53)	0.41
Body mass index (kg/m ²)	≥ 30 vs <30	3.08 (2.62,3.64)	1.80 (0.88,3.68)	0.14	2.51 (1.73,3.63)	1.88 (0.88,4.02)	0.22
Frequency of vigorous physical activity	3+ times/week vs. never/rarely	0.77 (0.63,0.94)	0.37 (0.15,0.95)	0.13	0.64 (0.38,1.09)	0.60 (0.23,1.54)	0.14
Alcohol intake	≥ 24 grams/day vs 0 grams/day	0.96 (0.66,1.38)	-	-	0.85 (0.33,2.43)	-	-
Smoking status	Ever vs. never smoker	0.88 (0.75,1.04)	0.44 (0.21,0.90)	0.40	0.91(0.64,1.30)	0.93 (0.46,1.89)	0.87
Diabetes	Yes vs. no	1.16 (0.89,1.52)	2.40 (0.95,6.05)	0.44	1.59 (0.93,2.74)	1.11 (0.33,3.77)	0.20
1st degree family history of breast cancer	Yes vs. no	0.71 (0.54,0.93)	2.77 (1.28,5.99)	0.002	0.93 (0.53,1.63)	2.47 (1.10,5.54)	0.12
1st degree family history of other cancer	Yes vs. no	1.00 (0.85,1.18)	1.81 (0.90,3.63)	0.48	0.82 (0.56,1.21)	1.00 (0.48,2.11)	0.38

a Defined as in the main analysis.

b Adjusted for age (continuous), OC use (ever/never), MHT use (ever/never), parity (nulliparous,1,2,3+), BMI (<30 vs 30+ kg/m²), menarche (<13, 13-14, 15+ years), age at menopause (premenopausal, <45, 45-49, 50-54, 55+ years), and smoking status (never, former, current smoker). Unknown/missing set as a separate category within each factor.

c P value from logistic regression of case-only analysis of histological types comparing each risk factor, adjusting for same covariates as above and person-years.